SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value (SABS) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2023 to Q4 2025

Type / Class
Equity / Common Stock, $0.0001 par value
Symbol
SABS on Nasdaq
Shares outstanding
49,603,188
Price per share
$3.94
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
18,100,153
Total reported value
$67,694,610
% of total 13F portfolios
0%
Share change
+3,301,171
Value change
+$12,513,548
Number of holders
30
Price from insider filings
$3.94
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value (SABS) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Vivo Opportunity Fund Holdings, L.P. 10% $54,973,720 25,931,000 Vivo Opportunity Fund Holdings, L.P. 29 Sep 2025
Woodline Partners LP 9.9% $14,323,021 7,125,881 Woodline Partners LP 30 Sep 2025
BIOTECHNOLOGY VALUE FUND L P 10% $10,386,912 5,167,618 BVF PARTNERS L P/IL 30 Sep 2025
Commodore Capital LP 9.9% $9,588,711 4,522,977 Commodore Capital LP 26 Sep 2025
RA CAPITAL MANAGEMENT, L.P. 9.9% $9,331,180 4,401,500 RA Capital Management, L.P. 26 Sep 2025
PERCEPTIVE ADVISORS LLC 7.3% $13,088,916 3,471,861 Perceptive Advisors LLC 14 Jan 2026
RTW INVESTMENTS, LP 3.2% -68% $6,253,970 +$2,218,090 1,587,302 +55% RTW Investments, LP 31 Dec 2025

As of 31 Dec 2025, 30 institutional investors reported holding 18,100,153 shares of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value (SABS). This represents 36% of the company’s total 49,603,188 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value (SABS) together control 58% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Vivo Capital, LLC 23% 11,420,000 0% 2.8% $42,710,800
Commodore Capital LP 8.9% 4,401,500 0% 1.1% $16,461,610
Woodline Partners LP 5.7% 2,850,881 0% 0.04% $10,662,295
Spruce Street Capital LP 4.4% 2,198,502 0% 2.7% $8,222,397
Sessa Capital IM, L.P. 4.4% 2,198,457 0% 0.16% $8,222,229
VANGUARD GROUP INC 3.7% 1,847,136 +405% 0% $6,908,288
Propel Bio Management, LLC 1.3% 652,881 2.1% $2,441,775
Jefferies Financial Group Inc. 1.2% 580,328 0.02% $2,170,427
Balyasny Asset Management L.P. 0.96% 475,439 0% $1,778,142
MILLENNIUM MANAGEMENT LLC 0.65% 324,090 0% $1,212,097
HB Wealth Management, LLC 0.62% 307,500 0% 0.01% $1,150,050
AMERIPRISE FINANCIAL INC 0.57% 283,645 0% $1,060,833
MARSHALL WACE, LLP 0.48% 236,460 0% $884,360
Simplify Asset Management Inc. 0.42% 208,227 0.01% $778,769
AWM Investment Company, Inc. 0.4% 200,000 0% 0.07% $748,000
STEMPOINT CAPITAL LP 0.3% 146,558 0.09% $548,127
GEODE CAPITAL MANAGEMENT, LLC 0.24% 119,517 +39% 0% $447,037
ExodusPoint Capital Management, LP 0.17% 86,113 0% $322,063
GOLDMAN SACHS GROUP INC 0.1% 51,348 +358% 0% $192,042
Pathstone Holdings, LLC 0.1% 50,650 0% 0% $189,433
OMERS ADMINISTRATION Corp 0.08% 42,000 0% $157,080
Qube Research & Technologies Ltd 0.06% 31,147 0% $116,490
CITIGROUP INC 0.06% 29,974 +3503% 0% $112,103
Verition Fund Management LLC 0.05% 26,867 0% $100,483
Persistent Asset Partners Ltd 0.04% 19,790 0.04% $74,015

Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, $0.0001 par value (SABS) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 18,100,153 $67,694,610 +$12,513,548 $3.74 30
2025 Q3 28,023,938 $56,328,113 +$52,469,483 $2.01 34
2025 Q2 1,923,874 $3,369,565 -$378,633 $1.76 25
2025 Q1 2,209,552 $2,994,479 -$1,776,863 $1.36 26
2024 Q4 2,652,300 $10,189,778 -$1,266,185 $3.79 26
2024 Q3 3,141,736 $8,482,377 +$68,507 $2.70 24
2024 Q2 3,127,151 $9,694,108 -$923,501 $3.10 21
2024 Q1 3,339,666 $15,162,138 -$15,603,353 $4.54 23
2023 Q4 8,791,109 $6,055,351 +$6,055,351 $0.69 3